The United States filed a complaint under the False Claims Act (FCA) against Regeneron Pharmaceuticals Inc. (Regeneron), a New York-based pharmaceutical company. Regeneron manufactures and sells Eylea, an anti-vascular endothelial growth factor inhibitor approved by the Food and Drug Administration to treat, among other conditions, neovascular Age-Related Macular Degeneration, a prevalent, usually age-related condition that impairs vision. Read More
Home » False Claims Act Complaint Filed Against Regeneron Pharmaceuticals for Fraudulent Drug Pricing Reporting
False Claims Act Complaint Filed Against Regeneron Pharmaceuticals for Fraudulent Drug Pricing Reporting
Related Posts
Owner of Arkansas Tree Service Business Sentenced for Tax Fraud
An Arkansas man was sentenced to 20 months in prison for filing a false individual income tax return. Read More
Illinois Man Sentenced for Preparing False Tax Returns
An Illinois tax return preparer was sentenced to 16 months in prison for preparing and filing false tax returns for clients. Read More
Justice Department Releases Sixth Annual Elder Justice Report
Earlier today, the Justice Department issued its sixth Annual Report to Congress on its efforts to combat elder fraud and abuse. The report summarizes the… BronJustice Department Releases Sixth Annual Elder Justice Report